Company profile
Motus GI Holdings, Inc.
OTC: MOTS · Healthcare · Medical - Devices
#977 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 33GM —SS 26
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, Piotroski F · ↓ market scale, return on equity
Methodology →Revenue TTM
$327.0k
Rev growth YoY (TTM)
-47.9%
Net income (FY)
-$12.9M
Employees
15
as of 2026-07-12
Market cap
$639
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$295.0k$295.0k2023
Net income-$12.9M-$12.9M2023
Operating income-$11.9M-$11.9M2023
Total assets$7.2M$7.2M2023
Liabilities$4.5M$4.5M2023
Equity$2.7M$2.7M2023
Revenue trend
FY2018 – FY2023 · USD
FY18
FY19
FY21
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Motus GI Holdings, Inc.’s revenue?
Motus GI Holdings, Inc. booked $295.0k in FY2023 revenue, contracting 45% year over year — slower than 80% of Healthcare companies we track, at a -4361.7% net margin.
Peers · Healthcare
BioAtla, Inc.15DABVC BioPharma, Inc.41DTempest Therapeutics, Inc.24DCannAmerica Brands Corp.——Hydrogen Hybrid Technologies, Inc.——Aion Therapeutic Inc.——Neighbors
Broward →Key facts
CEOMark Pomeranz
SectorHealthcare
IndustryMedical - Devices
HeadquartersFort Lauderdale, FL
ExchangeOTC: MOTS
Employees15
IPO date2018-02-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.